THE USE OF SEBEKTAN IN THE TREATMENT OF CHRONIC CHOLECYSTITIS

Issue: 
3
Year: 
2016

V.V. Karabaevа
Senior Research Scientist, Department of the Experimental and Clinical Pharmacology, Medical Center,
All-Russian Research Institute of Medicinal and Aromatic Plants (Moscow)
E-mail: vera-karabaeva@rambler.ru
S.A. Vichkanovа
Dr.Sc. (Biol.), Professor, Department of the Experimental and Clinical Pharmacology, Medical Center,
All-Russian Research Institute of Medicinal and Aromatic Plants (Moscow)G.F. Sidelnikova
Research Scientist, Department of the Experimental and Clinical Pharmacology, Medical Center,
All-Russian Research Institute of Medicinal and Aromatic Plants (Moscow)
A.R. Jumayan
Head of Branch № 4, Consultative-Diagnostic Policlinic № 121 (Moscow)
N.V. Andrianova
Physician-Methodologist, Consultative-Diagnostic Policlinic № 121 (Moscow)

The paper presents facts concerning the original national complex medicine of sibektan which contains: tanatsehol (25 mg) (Tanacecholum), silimar (30 mg) (Silymarum), dry extract of birch (20 mg) (Betula pend) and dry extract of tutsan(25 mg) (Hypericum perforatum L). It was first used to treat patients with chronic cholecystitis in outpatient setting. There are the results of treatment of 46 patients aged from 20 to 72 years female (39) and male (7) with chronic cholecystitis, with disease duration from 2 to 12 years in remission. The most patients’ (79%) disease was on the background of comorbidities: coronary heart disease, GB, DM, NAFLD, dyslipidemia, obesity, overweight. The main symptoms, which patients had reported were the severity, discomfort in the right hypochondrium, the most frequently bitter taste in the mouth, belching, nausea. All the patients were conducted by laboratory tests: general blood analysis, biochemical tests and ultrasound of the abdominal organs. Sibektan was prescribed as 2 tablets 3 times a day 20-30 minutes before meals for 20-25 days due to the treatment of comorbidities. At the end of treatment the dynamics of the main clinical symptoms, biochemical data studies and ultrasound was taken into cosideration. The degree of pain and dyspeptic syndromes were scored (0 to 4). The analysis of treatment results showed the reduction or disappearance of pain and dyspeptic syndromes, improvement of biochemical parameters. The feature of the use of sebektan is the improvement of biochemical parameters of patients with concomitant NAFLD in a stage of fatty hepatosis.

Keywords: 
words: sibektan
chronic cholecystitis
biliary sludge
choleretic
hepatoprotective
biochemical
ultrasound.